問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Cardiovascular Diseases

Division of Neurology

Division of Endocrinology

更新時間：2024-06-13

林維文LIN, WEI-WEN
  • Principal Investigator
  • Clinical Trial Experience (year)

  • weinlinecho@gmail.com

Recruiting Trial

15Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林維文

List

24Cases

2019-05-02 - 2026-01-17

Phase III

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  • Condition/Disease

    Coronary Heart Disease (CHD)

  • Test Drug

    Repatha

Participate Sites
10Sites

Recruiting9Sites

Terminated1Sites

2019-12-01 - 2020-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy

  • Condition/Disease

    Drug-Resistant Epilepsy/Focal-Onset Seizures

  • Test Drug

    Padsevonil

Participate Sites
8Sites

Terminated8Sites

2020-03-17 - 2024-05-02

Phase III

A multicenter, randomized, double-blind, parallelgroup, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction >= 40%. (LVEF >= 40%)

  • Condition/Disease

    heart failure

  • Test Drug

    Finerenone/ BAY 94-8862

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2021-09-01 - 2022-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting10Sites

Terminated2Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB